Key result
Across 22 studies, treatment of sepsis with RAAS inhibitors decreased rates and severity of sepsis-induced acute kidney injury and improved survival outcomes.
Why the study?
The pathogenesis of sepsis-induced acute kidney injury is not completely understood, resulting in nonspecific and responsive treatment, while the renin-angiotensin-aldosterone system may play a role.
Do RAAS antagonists reduce the rates and severity of sepsis-induced acute kidney injury in human and animal subjects?
Systematic Review (n=22)
Do RAAS antagonists reduce the rates and severity of sepsis-induced acute kidney injury in human and animal subjects?
RAAS antagonists may serve as a promising therapeutic option to decrease renal tissue damage, reduce S-AKI rates, and improve survival in sepsis.
BACKGROUND: Sepsis is a life-threatening condition responsible for up to 20% of all global deaths. Kidneys are among the most common organs implicated, yet the pathogenesis of sepsis-induced acute kidney injury (S-AKI) is not completely understood, resulting in the treatment being nonspecific and responsive. In situations of stress, the renin angiotensin aldosterone system (RAAS) may play a role. This systematic review focuses on analyzing the impact of the RAAS on the development of S-AKI and discussing the use of RAAS antagonists as an emerging therapeutic option to minimize complications of sepsis. METHODS: Studies were identified using electronic databases (Medline via PubMed, Google Scholar) published within the past decade, comprised from 2014 to 2023. The search strategy was conducted using the following keywords: sepsis, S-AKI, RAAS, Angiotensin II, and RAAS inhibitors. Studies on human and animal subjects were included if relevant to the keywords. RESULTS: Our search identified 22 eligible references pertaining to the inclusion criteria. Treatment of sepsis with RAAS inhibitor medications is observed to decrease rates of S-AKI, reduce the severity of S-AKI, and offer an improved prognosis for septic patients. CONCLUSION: The use of RAAS antagonists as a treatment after the onset of sepsis has promising findings, with evidence of decreased renal tissue damage and rates of S-AKI and improved survival outcomes. REGISTRATION: INPLASY202360098.
No takes yet. Share an insight, caveat, or question.
Tibi et al. (2023) conducted a systematic review in Sepsis-induced acute kidney injury (S-AKI) (n=22). RAAS inhibitors was evaluated on Rates of S-AKI, severity of S-AKI, and prognosis. Across 22 studies, treatment of sepsis with RAAS inhibitors decreased rates and severity of sepsis-induced acute kidney injury and improved survival outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: